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The  evolutionary progression  from  an  initial carcinogen-exposed target  cell  to  a 
cancer cell is characterized by a series of alterations in heritable phenotypic properties 
of the cells (1). Obviously, malignant cells that succeed in forming progressive tumors 
must have developed some means of subverting relevant host defenses and homeostatic 
control  mechanisms.  Thus,  an  analysis of how  potentialiy  malignant  ceils change 
when  they  acquire  progressive growth  behavior  in  normal  mice  should  help  us  to 
understand the hierarchy and relative importance of the different naturally occurring 
defense  mechanisms,  including immunologic ones.  Using this  general approach,  we 
have recently shown  that  the ultraviolet (UV)l-induced  1591  regressor fibrosarcoma 
(1591-RE) could evade the T  cell-mediated immunity of the host by the heritable loss 
of a  1591-RE tumor-specific transplantation antigen (2). This implied that the T  cell 
recognition of this antigen played an important  role in the rejection of the regressor 
tumor by normal mice. On the other hand, natural killer (NK) cells probably did not 
play  a  major  role  in  the  rejection  of this  tumor  since  progressor  variants  did  not 
demonstrate a  loss in sensitivity to NK cells. 
Macrophages  (M0)  can show highly selective cytotoxicity towards malignant cells 
in vitro (3) and there is some evidence suggesting that Mqb may also destroy neoplastic 
cells in vivo (see ref. 4  for review). These data support but do not rigorously test the 
proposition that M0 exert a surveillance function against the outgrowth of potentially 
malignant  cells  (4).  In  the  present  study  we  have  extended  the  type  of approach 
referred to above to determine the role of the M0 in the resistance of normal mice to 
1591-RE  tumor cells in  vivo. We discovered that  all of the  host-selected progressor 
variants  showed  a  heritably  reduced  sensitivity to  cytotoxic  M~.  Furthermore,  we 
found  that  this change  could  occur  independently  of the  loss of the  tumor-specific 
antigen in vitro, but that selection in vivo for tumor cells with decreased macrophage- 
sensitivity only occurred when the host also exhibited functional tunaor-specific T  cell 
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immunity. This suggested that both T  cells and maerophages acted together in vivo 
to suppress the outgrowth of potentially malignant cells in normal mice. 
Materials and Methods 
Mice.  5-10-wk-old female C3H/HeN (mammary tumor-virus negative) and BALB/e mice 
were  from a  colony of germ-free-derived, specific  pathogen-free animals purchased from the 
National Cancer Institute Frederick Cancer Research  Facility. They were  kept  at  the  La 
Rabida Institute in laminar flow hoods and were given sterilized food (Purina 5010C  [Ralston 
Purina Co., Chow Div., St. Louis, MO] for autoclaving) and water. The original stock of nude 
C3H/HeN mice were in the 23rd backcross  generation when they were obtained from a colony 
at the Biology Division of the Oak Ridge National Laboratory. 
Effector Cells.  Peritoneal M~ from mice injected intraperitoneally 5 d previously with 2 ml 
Brewer's Thioglycollate medium (0236-02;  Difco  Laboratories, Detroit,  MI)  were collected, 
enumerated, and purified (5). Over 95% of the purified cells belonged to the M~ series, as 
assessed  by morphology, avid uptake of neutral red, and phagocytosis of heat-killed yeast, 
colloidal carbon, and antibody-coated sheep erythrocytes. M~ were activated (6) by incubating 
for  5 h  in 200 #1  minimal essential medium (410-1100;  Grand Island Biological  Co., Grand 
Island, NY) containing 10% fetal bovine serum, 100 ng/ml purified bacterial lipopolysaccharide 
(LPS) (3122-25; Difco Laboratories), and 10% secondary mixed lymphocyte culture supernatant 
containing lymphokines (LK)  prepared  as  described  (7). Cytolytic T  cells  specific  for  the 
parental 1591 regressor tumor (referred  to here as 1591-RE) were generated in vitro from spleen 
cells of 1591-RE-immunized animals (2). 
Target Cells.  The fibrosarcomas 1591-RE and 2240 were induced in C3H/HeN (mammary 
tumor virus negative) mice by repeated exposure to ultraviolet radiation (8). These fibrosarco- 
mas  have  non-cross-reacting, tumor-specific transplantation antigens (9)  and  are  strongly 
immunogenic in that they regress when transplanted into young syngeneic mice, after an initial 
growth during the first  1-2 wk. Eight progressively  growing variants of the 1591-RE  parental 
tumor  developed  in  8  out  of  200  immunocompetent  1591-RE-challenged  mice,  and  are 
designated as 1591-PRO tumors (2). Tumors derived by passaging the 1591-RE tumor through 
syngeneic athymic nude, idiotypically suppressed (10), or  1591-PRO.3-bearing animals, were 
designated as  1591-NU,  1591-ID, and  1591-PB tumors, respectively.  All of the fibrosarcomas 
used in this study grow progressively  in syngeneic nude mice or in mice that are immunosup- 
pressed  by either UV irradiation or adult thymectomy and x irradiation, and eventually kill 
these hosts  (8). 
Using previously described methods (2), tumors were adapted to growth in vitro, expanded 
within 2 wk of explantation, and cryopreserved in aliquots (11) unless otherwise indicated. 
Whenever tumor cells were required for experiments, selected  frozen aliquots were thawed and 
used within 24 h. For tumor challenge, l-mm  3 fragments of solid tumor that had grown in a 
nude mouse were  implanted subcutaneously in each  inguinal area, or cell  suspensions were 
injected subcutaneously underneath the ventral skin. 
Normal syngeneic fibroblast lines (referred  to as  HLF) were derived from heart and lung 
tissue  (2). The  mastocytoma  P815  and  the  Moloney virus-induced lymphoma YAC  were 
maintained in vitro in supplemented RPMI 1640 (12). All cell lines used in these experiments 
were routinely examined for and found to be free of mycoplasma contamination  using bacterial 
culture as well as Hoechst 33258 DNA staining techniques. 
Cytotysis Assay.  The degree of T cell-mediated or macrophage-mediated lysis of tumor cells 
prelabeted with chromium-51 was determined as described (2). Briefly, tumor cells were labeled 
with 100/ICi 51Cr for  1 h and then 1 X 104 of the labeled tumor cells were added to individual 
wells of flat-bottomed 96-well  plates  (76-003-05;  Linbro Scientific, Hamden, CT)  (0.28 cm  2 
growth  area  per  well)  containing various numbers of washed  T  cells  or  Mq~. Incubation 
continued for 6 or 16 h, respectively, unless otherwise indicated. The percentage of specific lysis 
was calculated by the formula: [(experimental release-spontaneous release)/(total release-spon- 
taneous release)]  ×  100. 
Cytostasis Assays.  Mq~-mediated  inhibition of tumor cell  growth was determined by meas- 
uring [aH]thymidine ([aH]TdR) incorporation (5). Briefly,  1.0 gCi oft3H]TdR was added 24 h 
before harvest to individual wells of 96-well plates containing 2 ×  10'  tumor cells and varying 644  MACROPHAGE-RESISTANT PROGRESSOR  TUMOR VARIANTS 
numbers of M~. A 'SICr postlabeling assay  (5) was also used to measure M4~-mediated growth 
inhibition of tumor cells.  Briefly,  2 ×  103 tumor cells and varying numbers of Mq~ were  co- 
cultured in quadruplicate microwells  for up to 4 d, washed, and labeled for  1 h with 2.0 p.Ci 
5~Cr. Under standard conditions, the labeling of target cells was always  10,000-30,000  cpm/ 
well. With both types of cytostasis  assays,  controls consisting of M4, alone were run in each 
experiment but isotope uptake by these cells was negligible (<200 cpm) and therefore not taken 
into account. The percentage target cell growth inhibition was calculated as follows:  100 ×  ~1 
-  ([cpm(target cells +  M~)]/[cpm(target cells alone)])].  Under the above assay conditions, Mq, 
were  equally effective  in inhibiting tumor cell growth whether derived from  normal, T  cell- 
deficient  (nude),  or  allogeneic  animals, provided  that  the  peritoneal  cells  had  first  been 
activated in vitro by incubating in LPS and secondary mixed lymphocyte culture supernatant 
containing lymphokines (LK)  as described above. For example, in two separate experiments 
activated M 4, from normal or nude C3H or BALB/c mice inhibited the growth of 1591-RE 
tumor cells  74-81%  at  an effector/target cell  ratio  (E/T)  of 1:1, and 33--43% at  an E/T of 
1:400. The mean percent growth inhibition using nonactivated cells from these same groups of 
animals was only 14-t9% at an E/T of 1:1, and 2-7% at an E/T of 1:400. The above data 
suggest  that the adherent effector cell is probably not a mature T  cell but most likely belongs 
to  the M4~ series  (6,  13-15).  The effects  observed in this assay  do not appear to reflect  the 
depletion of essential nutrients such as arginine (16), since in repeated experiments, supernatants 
from  4-d primary cultures containing activated Mq, and  1591-RE  tumor cells  (average 83% 
tumor cell  growth  inhibition) did not transfer significant cytotoxicity to secondary cultures 
containing 1591-RE  tumor cells alone (average <1% tumor cell growth inhibition). 
Antisera.  In some experiments, effector cells were depleted of M~ by incubation with a  1:4 
dilution of an  anti-LyM-l.1  antisera  (AST-101,  ref. 17)  for  45  min  at  4°C,  followed  by 
incubation with rabbit complement (final dilution 1:2) for 45 rain at 37°C. The anti-LyM-l.  1 
antisera was  a  generous gift  of Dr.  R.  C.  Burton, The University of Newcastle,  Newcastle, 
Australia. Using the same general procedures, effector cells were depleted ofThy-1.2  + or Lyt-2  + 
cells using a  1:50 dilution of an anti-Thy-l.2 hybridoma antibody (AT83AB)  or a  1:2 dilution 
of anti-Lyt-2 hybridoma antibody  (2.155.2),  both  obtained  from  Dr.  F.  W.  Fitch  of this 
University. 
Results 
Selection In  Vitro  for 159/-RE  Variants with Low M~ Sensitivity.  First, we analyzed the 
differentiation markers  and  activation requirements of the  M~  to  be  used  for  the 
selection of MqS-resistant variants in vitro. We found that adherent peritoneal exudate 
cells activated  by exposure  to  both  LPS  and  LK exhibit marked cytolytic activity 
towards  1591-RE fibrosarcoma cells, but not towards normal HLF fibroblasts, in an 
8- or  16-h SlCr release assay  (Table I). This reactivity appeared  to  be mediated by 
Mq,  and  not  by  contaminating nonadherent T  cells  because  it  was  almost  totally 
abolished by pretreatment with anti-LyM-l.1 antiserum (17)  and complement, but 
not by pretreatment with either anti-Thy-  1.2 antiserum and complement or anti-Lyt- 
2 antiserum and complement (Table I). Although  1591-RE tumor cells appeared to 
be highly sensitive to activated M~, we  found in further experiments that  a  few of 
these  tumor cells always survive even prolonged treatment with  these  effector cells 
(e.g., <1% survival after  120 h treatment, E/T =  20: 1). We questioned whether these 
tumor cells represented variants with a  decreased sensitivity to M4,-mediated killing. 
To test  this possibility, we seeded 3 ×  105  1591-RE tumor cells into each of two  150- 
cm  2  tissue  culture  flasks,  each  containing 6  ×  106  activated  Mq~. After  120  h  of 
incubation, the tumor cells were primarily localized to  3-10 clusters per flask, each 
cluster containing 10-30 cells. In contrast, control flasks containing 1591-RE tumor 
cells alone or  1591-RE tumor cells plus nonactivated macrophages displayed a  near 
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TABLE  I 
Differentiatton Markers and Activation Requirements  In  Vitro of Adherent Peritoneal  Exudate Cells 
Medtating Cytolysis of 1591-RE Tumor Cells 
Lysis of target cells§ 
Mode of activa-  Pretreatment of 
Target cells  tion of effector  effector cells:l:  50:1  10:1  2:1 
cells* 
8h  16h  8h  16h  8h  16h 
%  %  % 
1591-RE  LPS +  LK  None  31  70  18  43  8  17 
C alone  --II  78  --  42  --  17 
C + anti-Thyl.2  --  82  --  40  --  25 
C +  anti-Lyt-2  --  79  --  44  --  14 
C + anti-LyM-l.l  --  17  --  5  --  3 
1591-RE  LPS alone  None  6  18  2  6  2  6 
HLF  LPS +  LK  None  2  1  1  -3  2  0 
* Adherent thioglycollate-elicited  peritoneal exudate cells were cultured for 5 h in medium containing 100 
ng/ml purified bacterial LPS alone or in combination with 10% LK. 
:~ Activated M~ were treated with antisera and/or complement  (C)  before  the addition of tumor target 
cells. The lytic activity of 1591-RE tumor-specific  T cells generated in an MLTC was reduced from 64% 
to <5% by pretreatment with C and either anti-Thy-1.2 or anti-Lyt-2, but was not significantly affected 
by pretreatment with C and anti-LyM- 1.1  (data not shown). 
§ Mth were tested in an 8-h and  16-h 51Cr release assay against  1591-RE or HLF target cells at the indicated 
E/T ratios. An E/T of 50:1 corresponds  to a M~ population density of 1.8 ×  104/mm 2. 
[I Not tested. 
selectively dislodged  from the plastic by replacing the medium  with 5  ml versene for 
5  rain,  a  procedure  that  did  not  remove M~  in  control  flasks  containing  M~  alone. 
The  tumor  cells were  expanded  in  the  absence  of Mth  for cryopreservation  after  an 
additional  cycle of exposure  to  activated  Mq~  (there  was  no  apparent  inhibition  of 
tumor  cell growth  during  the second  exposure  to M~).  Two  cell lines independently 
derived in the above manner  were designated  1591-Mth. 1 and  1591-M~.2.  To test for 
the stability of the altered phenotype of the tumor cells,  1591-Mth. 1 was also passaged 
once  through  a  nude  C3H  mouse,  readapted  to  tissue  culture,  and  cryopreserved. 
This cell line was designated  1591-M~. 1.NU. 
To  determine  if these  M~-selected  cell  lines  showed  increased  resistance  to  M~- 
mediated  cytolytic activity in vitro, we tested tumor cells from each of these cell lines 
or  from  the  parental  1591-RE  tumor  for sensitivity  to  activated  Mt  h  in  a  16-h  51Cr 
release assay. The pooled results of five such assays,  analyzing the response to all three 
1591-M~  cell lines,  are presented  in  Table  II.  In agreement  with  the data  presented 
in  Table  I,  1591-RE  tumor  cells  were  lysed  by  Mth  that  had  been  activated  by 
lipopolysaccharide  and  lymphokines.  In  contrast,  the  1591-M~  tumor  cells  were 
completely unaffected  by the presence of these effector cells. This differential suscep- 
tibility  could  not  be  explained  by  differences  in  the  spontaneous  and  maximum 
release of radiolabel  because these parameters  were almost  identical for the two types 
of cell  lines.  Table  II  also  shows  that  under  these  conditions,  tumor  cells  from  the 
relatively NK-resistant  P815 tumor  (14,  18) were lysed to a  significant degree, whereas 
tumor  cells  from  the  highly  NK-sensitive  YAC  tumor  (18)  were  only  moderately 
affected.  This  pattern  of reactivity  is  consistent  with  Mth-mediated  killing  but  not 
with  NK-mediated  killing  (14,  18).  The  resistance  of 1591-M~  to  Mth has  remained 
stable  over 2  mo of continuous  culture  of the cell lines, and  was  retained  by  further 646  MACROPHAGE-RESISTANT  PROGRESSOR  TUMOR  VARIANT5 
TABLE  II 
Resistance of the M~-selected Tumor Cell Variants (1519-Meo)  to Lysis t~y Activated M~ 
Target cells  E/T*  Mode of activation  Release of S'Cr  Lysis of 
target cells 
1591-RE  Spontaneous release  --  2672  +-- 143~  0 
Maximum release  --  9501  ±  367  100 
5(1:1  LPS alone  3052  +  167  6 
25:1  LPS alone  3152  +  199  7 
I2:l  LPS alone  3076  +  188  6 
50:1  LPS +  LK  7176 +  337  66 
25:1  LPS +  LK  7190 +  359  66 
12:1  LPS +  LK  4292  +  347  24 
[ 59 L-M0  Spontaneous release  --  2513  +  119  0 
Maximum release  --  9471  ±  423  100 
50:1  LPS alone  2282  ±  254  -3 
25:1  LPS alone  2406  -- 320  -2 
12:l  I.I)S alone  24(.)0 +  294  0 
5(t:1  I.PS +  LK  271l  ±  301  3 
25:1  I.PS +  I,K  2426  +  231  -1 
12:1  I,PS +  I,K  2691  +  294  3 
P815  Spontaneous release  --  998 +__ 223  0 
Maximum release  --  3126  +  65  100 
50:l  LPS alone  t075 _+  106  4 
25:1  LPS alone  I089 +_ 56  4 
i2:1  t.PS alone  ~048 +  56  2 
50:1  I.PS +  LK  2376  +  239  65 
25:1  I.PS +  LK  2336  ±  131  63 
12:1  1.PS +  I.K  1453 +  102  21 
YAC  Spontaneous release  --  1841) -+- 48  0 
Maximum release  --  :-)278 ±  93  100 
50:1  LPS alone  1716 ±  159  -4 
25:1  LPS alone  1879 ±  282  I 
12:1  LPS alone  1757 ±  123  -2 
50:1  LPS +  LK  2644  ±  115  23 
25:1  I.PS +  LK  2471  ±  35  18 
12:1  LPS +  LK  2458  ±  22  18 
* 1 ×  104 alCr-labeled tumor target cells were cultured in normal growth medium (spontaneous release),  in 
saponin-comaining medium (maximum release),  or in normal growth medium containing effector M0 at 
the indicated E/T ratios, and the release  of radiolabel from the target cells was determined  16 h later. An 
E/T of 50:1 corresponds to a MqS population density of 1.8 ×  104/ram  2. 
:~ Mean  +  SEM  for five independent experiments, two analyzing  1591-M~.1,  two analyzing  1591-Mob,2, 
and one analyzing 1591-M0.1.NU. 
passage  of  these  cell  lines  through  nude  mice;  thus  it  appears  that  the  low  Mqb- 
sensitivity  of  these  Mq~-selected  cell  lines  is  a  stable  heritable  characteristic.  In 
agreement  with  the  above  findings,  microscopic  examination  of  M0-tumor  cell 
cultures  revealed  a  marked  inhibition  of  1591-RE,  but  not  of  1591-M0,  tumor  cell 
growth  during  a  4-d  observation  period.  This  cytotoxic  effect  was  confirmed  by 
analyzing  for the incorporation  of [aH]TdR  by the tumor  cells during  this time period, 
and  by postlabeling  the residual tumor  cells with 51Cr.  The  pooled  results of five such 
experiments,  analyzing  all  three  of  the  1591-M~  cell  lines  described  above,  are 
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FIG.  l.  Lack of M~-mediated growth inhibition of 1591-RE tumor variants selected  in vitro for 
resistance  to activated Mdp. Activated Mff were added at day 0 to the parental  tumor cells (t591- 
RE) or the variant tumor cells (1591-Mdp) at three different  E/T ratios  (20:1 [D], 1:1 [A], t:20 [V], 
no Mdp [0] for the measurement of target cell [aH]TdR  incorporation (upper panels);  1:1 [0],  1:20 
[A],  l:400 [~],  no M(b  [0]  for the measurement  of target  cell '~lCr postlabeling  [lower panels]). 
Vertical bars represent  the SEM for five separate experiments, three analyzing 1591-M~b.l and two 
analyzing 1591-M~b.2; each experiment included 1591-RE tumor cells as concurrent controls. 
to  an  altered  growth  rate  of the  cells,  since  the  [3H]TdR  incorporation  and  51Cr 
postlabeling  at  each  time  point  was  not  significantly  different  from  that  of  the 
parental  1591-RE  tumor. 
Analysis of Host-selected Progressor Variants for Mdp-sensitivity.  The  above experiments 
demonstrated  that  Mff which  have  been  activated  by  lymphokines  released  from  T 
cells can select for Mff-resistant  variants  in vitro; in the next series of experiments, we 
determined  whether  the  intact  host  would select  for similar Mff-resistant  variants  in 
viva. Our approach  was based on the fact that  the parental  regressor  1591-RE tumor 
occasionally  progresses  upon  transplantation  into  normal  immunocompetent  mice, 
due to the generation of progressor tumor  variants  (2).  We have previously described 
the isolation of such  variants  (referred to as  159 t-PRO  tumors)  and  have shown that 
all  of the  variants  have lost  a  1591-RE-specific transplantation  antigen  (2).  We now 
determined  if these  variant  tumors  had  also  lost  sensitivity  to  Mq~.  As  controls,  we 
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RE tumor fragments, and adapted them to tissue culture. Two such control tumor 
cell lines (1591-NU. 1, 1591-NU.2) were derived from congenitally athymic nude hosts, 
two  (1591-ID. 1,  1591-ID.2)  from  idiotypically-suppressed hosts  (experiment  2,  ref. 
10),  and one  (1591-PB.3)  from  a  host  that  already carried  a  progressively growing 
1591-PRO.3  variant tumor, a conditon that we recently discovered renders syngeneic 
mice highly susceptible to challenge with  1591-RE tumors (J.  Urban, manuscript in 
preparation). We have previously shown that spleen cells from these three different 
types  of hosts  were  unable to  generate  tumor-specific T  lymphocytes  in  a  mixed 
lymphocyte-tumor cell culture, whereas spleen cells from nonsuppressed control mice 
injected with  the  same  tumor  fragments  generated  these  T  cells  (2,  10).  We  then 
compared the ability of activated Md~ to inhibit the growth of each of these tumor cell 
lines in a  "51Cr release assay using the  1591-RE parental tumor as a  positive control 
and  the  1591-M  0  variant  tumors  as  negative controls.  The  pooled  results  of  five 
experiments are shown in Fig. 2. The left panel indicates that  1591-NU, 1591-ID, and 
1591-PB  tumors obtained from  the  three  types of immunodeficient mice described 
above were as sensitive to M0 as the parental 1591-RE tumor. In contrast, the middle 
panel shows that all of the rare progressor tumors (1591-PRO) isolated from normal 
T  cell-competent mice were uniformly less sensitive to M0 than the parental 159 I-RE 
tumor and almost as insensitive as the 1591-Mff variant tumors derived in vitro (right 
panel). To demonstrate that the  1591-PRO tumors are not only less sensitive to M0- 
mediated lysis, but also to growth inhibition mediated by M4~, the sensitivities of the 
different cell lines were compared in a  5]Cr postlabeling assay. The pooled results of 
five separate  experiments shown  in  Fig.  3,  similar to  the  results  shown  in  Fig.  2, 
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Flo. 2.  Decreased sensitivity to  M0-mediated lysis in host-selected progressor tumor  variants 
(1591-PRO) isolated after one passage of the parental  1591-RE tumor through mice possessing 
immunocompetent T  cells. The  1591-RE tumor was implanted subcutaneously into mice (NU, 
nude; ID, idiotypically  suppressed; PB, progressor-bearing;  PRO, normal). I mo later, the progres- 
sing tumors were adapted to growth in vitro and the resulting cell lines shown in the three panels 
were compared for M0 sensitivity  in a 16-h mCr release assay as described in Materials and Methods. 
An E/T of 200: [ corresponds to a M0 population density of 7.2 ×  104/ram  2. Vertical bars represent 
the SEM for five separate experiments, each including the parental  159J-RE tumor, at least one 
[591-PRO host-selected variant, and at least one 1591-M0 variant derived in vitro. 
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Fie.  3.  Decreased  sensitivity to M(#-mediated  growth inhibition of host-selected progressor tumor 
variants  (1591-PRO) isolated after one passage of the  parental  1591-RE tumor  through  mice 
~ossessing immunocompetent T cells. The various tumor cell lines  were tested as target cells in a 
Cr postlabeling assay using activated M~p as effector cells (for details on target lines  see legend to 
Fig. 2). Vertical bars represent the SEM for five separate experiments, each including the parental 
1591-RE tumor, at least one 1591-PRO host-selected variant, and at least one 1591-Mq) variant 
derived in vitro. 
demonstrate that selection for Mq)-resistance only occurred in mice possessing tumor- 
specific T  cell immunity. 
Independence of M(p-sensitivity and Expression of the 1591-RE Tumor-specific Antigen.  The 
data  above have demonstrated that  progressor variants selected  in vivo by normal 
immunocompetent mice regularly showed a  reduced sensitivity to Mff.  Because we 
had already shown (2)  that these variants had also lost a T  cell-recognized 1591oRE- 
specific tumor antigen, we tested whether there was an obligatory link between the 
loss of the  immunodominant 1591-RE  tumor-specific antigen and  the  loss of Mq)- 
sensitivity. We wanted to determine whether the  1591-Mq) tumor cell lines derived in 
vitro, which had lost M(#-sensitivity, were also less sensitive to tumor-specific -T cells 
directed against the  1591-RE tumor-specific antigen. We generated cytolytic  1591- 
RE-specific T  lymphocytes by culturing the spleen cells of 1591-RE-injected animals 
with  1591-RE  stimulator cells  for  6  d  in  a  mixed  lymphocyte-tumor cell  culture 
(MLTC)  and used  the  resulting T  cells as  effectors  in a  6-h 51Cr  release assay.  As 
shown in Fig. 4,  the  1591-M~) variants (right  panel) were  fully sensitive to  these T 
effector cells, whereas control 2240  tumor cells were  not  lysed. This indicated that 
Mff-sensitivity could be lost independently of the tumor-specific antigen recognized 
by T  cells, and supported  the  hypothesis  (19)  that  M~  do  not  recognize the  same 
antigen that  T  cells recognize. In addition, it confirmed that  the  1591-M~p  variant 
tumor cells derived in vitro were of the  1591  lineage, and that  the resistance of the 
1591-M(/)  tumor cells to Mq) was not solely due to a  general resistance of these tumor 
cells to lysis. As expected, the cytolytic T  cells effectively lysed the  1591-RE tumor as 
well as  all of the other  1591  tumors reisolated after passage of the  1591-RE tumor 650  MACROPHAGE-RESISTANT PROGRESSOR  TUMOR VARIANTS 
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Fro.  4.  Retention of the  1591-RE tumor-specific target antigen by the M~b-resistant 1591-M~ 
tumor cells. The indicated tumor cell lines were exposed to 1591-RE-specific  T cells in a 6-h '~Cr 
release assay. The specific T cells were generated in MLTC cultures using spleen cells from 1591- 
RE-immunized mice. Experiments shown in each panel were done independently of those shuwn in 
the other panels and were therefore individually controlled with 1591-RE and 2240 target cells used 
in each of the experiments. 
through T  cell-deficient mice (left panel). Confirming earlier results (10), the middle 
panel shows  that  all of the  1591-PRO tumors apparently lost the expression of the 
1591-RE antigen since they were not recognized by the MLTC cells. 
To further demonstrate that the  1591-M~ variants selected in vitro still possessed 
normal amounts of the parental  1591-RE antigen, we also tested the ability of these 
variant tumors to induce T  cell immunity in vivo. Normal animals were injected with 
fragments of the  1591-RE or  1591-M~ tumors, and 3 wk later their spleen cells were 
removed and restimulated with tissue culture cells from the respective tumor line in 
an MLTC. The resulting T  effector cells were tested in a  6-h 51Cr release assay using 
1591-RE and control 2240 tumor cells as targets. Fig. 5 shows the pooled results from 
four separate experiments, each analyzing the response to one of the three  1591-M~ 
variant tumors. While spleen cells of noninjected animals failed to generate significant 
cytolytic responses in vitro, injection of either the 1591-RE or 1591-M~ variant tumors 
primed spleen cells in vivo to produce high 1591-RE-specific cytolytic responses upon 
restimulation in culture. Thus the  1591-RE antigen appeared  to  be present on the 
M~-insensitive 1591-M~ variants and this antigen was recognized in vivo as well as 
in vitro. 
Growth Potential In  Vivo of M(p-resistant  Variants.  To  assess  the effect  of decreased 
M~-sensitivity on the tumorigenic potential of the  1591  tumor, we challenged normal 
or nude mice with fragments of each of the two M~-resistant variant tumors that had 
been selected in vitro, and that had retained the  1591-RE specific antigen. All of the 
nude mice injected with  1591-RE or the  1591-M~ variants died of progressive tumor 
growth, whereas all of the normal mice injected with tumors eventually rejected the 
tumor,  regardless  of the  tumor implanted. This  suggested  that  a  decrease  in  M~- 
sensitivity alone  was  not  sufficient  to  allow  for  tumor  progression.  Interestingly, IOO 
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Fl~.  5.  Retention of the  1591-RE  tumor-specific antigen by the Mdp-resistant  variant tumor cells 
(1591-Mq~), as shown by their capability to elicit  in vivo and restimulate in vitro  1591-RE-specific 
cytolytic T  cells. Injected mice received two l-ram  ~ fragments subcutaneously of either  1591-RE  or 
1591-M4~ tumors. 3 wk later, the spleen cells of these animals were restimulated for 6 d with 1591- 
RE  (left  and middle panels) or  1591-M~  (right panel)  tumor cells  in a  MLTC  culture, and  then 
tested in a 6-h ~Cr release assay against 1591-RE  or 2240 control tumor cells. Vertical bars represent 
the SEM for four separate experiments, two analyzing 1591-M4~.1 and two analyzing 1591-Mdp.2. 
however, there appeared to be repeatable differences between the 1591-RE and  1591- 
M~p tumors in tumor growth during the early phase of growth in normal mice before 
rejection  (Fig. 6, left panels).  Both of the  1591-Mq~ variants grew initially to a larger 
volume in normal mice than the parental  1591-RE control tumor. Furthermore, the 
time interval required for the complete rejection of the Mq~-resistant variants (average 
34 d) was slighly longer than for the  1591-RE tumor (average 17 d). No differences in 
the growth curves of the  1591-Mq~ and  1591-RE tumors were observed in nude mice 
(Fig.  6, right panels).  Similar results were found in a  separate experiment  (data not 
shown). 
Discussion 
We have demonstrated that tumor cell variants with greatly reduced sensitivity to 
M4~  can  be  selected  for  in  vivo  or  in  vitro.  In  neither  case  was  this  phenotypic 
alteration  related  to  the  acquisition  of a  general  resistance  to  lysis.  The  variants 
selected in vitro were still fully sensitive to 1591-RE tumor-specific T  cells (Fig. 4) and 
even the variants selected in vivo, which had lost the  1591-RE-specific antigen, were 
still fully sensitive to T  cells directed against a  different tumor antigen  (re['. 20, and 
J.  L.  Urban  and  H.  Schreiber,  manuscript  in  preparation).  At  present  we  do  not 
know the mechanism(s)  for the M#-resistance of the variants selected in vivo and in 
vitro. Mq~-mediated target cytolysis probably involves several independent  functions 
including  binding  to a  target  structure on the neoplastic cells  (21)  and subsequent 
mediation  of cytolysis (22).  The binding of M~ to certain  target structures present 
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Fro.  6.  Differences in growth kinetics of the parental  1591-RE tumors and the variant  1591-M~ 
tumors  in normal but not in nude mice. The tumors  were implanted subcutaneously in the shaved 
inguinal fossae of groups of 10 normal or 4 nude mice each, two l-ram  a fragments per mouse. The 
mean tumor size per mouse was measured  every 2 d thereafter with a caliper, and the tumor w~lume 
was  computed  as  the  average  product  of three  perpendicular  tumor  diameters.  Vertical  bars 
represent  the SEM fur the individual analysis of the number of mice indicated above. 
necessary  event  in  the  cytolysis  of these  targets  (21).  A  recent  study  comparing  a 
variety of other, different tumors  indicated  that  M4~ may still bind  to a  large number 
of target  ceils that  are  insensitive to  lysis  (23).  Therefore  the  difference between  our 
sensitive  and  resistant  targets  may  not  necessarily  be  a  consequence  of a  specific 
change  in  the  target  structure  on  the  tumor  cell recognized  by  M~b,  but  rather  may 
reflect differences  in  susceptibility  to  the cytolytic effects of M~  after binding.  Thus 
the variants  might  be more  resistant  to  the  damaging  effects of one or several of the 
lyric  substances  reported  to  be  secreted  by  Mq~,  such  as  hydrogen  peroxide  (24), 
neutral  protease  (22),  or arginase  (16).  For example,  it  has  been  shown  that  tumor 
cells can  differ markedly  in  their potential  to  repair  tbe oxidative injury  exerted  by 
M~b (24).  It will be interesting to determine whether the Mq~-resistant  variants selected 
in  vitro and  in  vivo subvert  M~-mediated  cytotysis  by  the same or different  mecha- 
nisms,  to gain  insight  into the relative importance  of these mechanisms. 
The  fact  that  we  found  M~  resistance  to  be  regularly  selected  for  in  vivo argues JAMES L.  URBAN AND HANS SCHREIBER  653 
strongly  for  the  relevance  of this  arm  of the  host  immunity  against  tumor  cells. 
Nevertheless,  we  found  independent  evidence  in  the  present  study  that  functional 
tumor-specific T  cells were also required  for the selection for Mq~-resistance to occur 
in  vivo. Thus,  such  selection  did  not  occur  in  mice  that  were  unable  to  generate 
tumor-specific T  cells, such as athymic nude mice or mice suppressed by the induction 
of antiidiotypic  immunity.  These  latter  mice could  only generate  tumor-specific T 
cells against  tumors  other  than  1591-RE  (10)  and,  as we show  here,  also  failed  to 
select  for Mdp-resistant  1591-RE  variants.  At  least  indirectly,  the  selection  for M~b 
resistance in vitro was also critically dependent on T  cells, since the Mt  h used for the 
selection had to be activated with lymphokines released by alloantigen-stimulated T 
cells (6, 25). The influence of immunologically committed lymphocytes on M(b activity 
in vivo and in vitro has been well documented (26, 27), although little information is 
available on the importance of this cell-cell interaction  in tumor rejection.  Interest- 
ingly, however, endotoxin-induced tumor regression of an established tumor has been 
shown  to  be  critically  dependent  upon  a  pre-existing  state  of anti-tumor  T  cell 
immunity (28), and this tumor rejection may, at least in part, be mediated by Mth. 
Mth-activating lymphokines are released by T  cells of the Lyt-1  + phenotype, and it 
has recently been proposed that these cells play a major role in allograft and possibly 
tumor rejection (for review see ref. 29). It is conceivable that a  major contribution of 
the tumor-specific T  cells or their factors lies in their ability to effectively attract Md? 
to the site of tumor growth. In this regard, it has been shown that Mth and T  cells are 
distributed  uniformly throughout  the tumor tissue of regressing Moloney sarcomas, 
but  only  infiltrate  the  margins  of progressively  growing  Moloney  sarcomas  (30). 
However, other studies analyzing UV-induced tumors have failed to reveal differences 
in M~ content between tumors which differed widely in immunogenicity and showed 
either regressive or progressive behavior in normal mice (31).  Furthermore, it has been 
shown that the Mt  h content of such tumors is unaltered even in UV-irradiated animals 
(31,  32),  which  develop  progressively  growing  tumors  after  implantation  of UV- 
induced regressor tumors. It is possible that the T  cells in mice bearing progressively 
growing UV-induced  tumors were effective in attracting the Md~ to the tumors but 
the host failed to activate the Mth sufficiently. Alternatively, the Mth content as well 
as their degree of activation may be comparable in regressing and progressing UV- 
induced tumors, but the progressor tumors may have acquired a decreased sensitivity 
to the M~, as observed in the present study. In this respect it is interesting that UV- 
irradiated  mice are only partially immunosuppressed,  and we have recently shown 
that  these  mice  therefore  select  for  the  outgrowth  of antigenic  progressor  tumor 
variants when challenged  with a  UV regressor tumor  (33).  It will be interesting to 
determine whether these variants show a relative decrease in sensitivity to Mth, similar 
to  the  progressor  variants  isolated  from  the  tumor-challenged  normal  mice  and 
described in this study. 
Previous  attempts  to  isolate  M~resistant  variants  after  selection  in  vivo  have 
apparently failed (34). One of the reasons for this may have been that the tumors that 
were  used  were  probably already  immunoselected  for  a  relative  resistance  to  M~ 
along  with  the  loss  of T  cell-recognized  antigens  at  the  time of their  isolation  as 
autochthonous tumors or after repeated transplantation  in normal mice. In contrast, 
the highly M~b-sensitive 1591-RE tumor line had been isolated from the autochthonous 
tumor of a mouse that was immunodeficient due to UV irradiation (8) and advanced 654  MACROPHAGE-RESISTANT PROGRESSOR TUMOR VARIANTS 
age  (35).  Interestingly,  other  malignant  cell  lines  which  have  been  derived  in  the 
absence of immunocompetent host  defenses, such  as cell  lines spontaneously trans- 
formed in vitro, also show extreme sensitivity to M~-mediated cytotoxicity (15). 
In conclusion, we show that immunoselection for Mq~-resistant progressor variants 
of the  1591-RE tumor occurs in vivo in the normal unimmunized host and that this 
selection  requires  an  intact  T  cell-mediated  tumor-specific immune  response.  This 
finding suggests that T cell-mediated activation of M~ is a relevant defense mechanism 
of normal  hosts against  1591-RE  tumor cells.  Thus it appears that T  cell-mediated 
tumor-specific immunity may protect  hosts  from the outgrowth  of 1591-RE  tumor 
cells by at least two differnt mechanisms:  (a) the direct destruction of the tumor cells 
by cytolytic T  cells, and (b) the T  cell-mediated activation of M~, which then actually 
effect  tumor  destruction.  Our  studies  suggest  that  the  conversion  of  the  highly 
immunogenic regressor tumor 1591-RE to a progressor tumor may require the loss of 
the strong regressor-specific tumor antigen  as well as a  decrease in the sensitivity to 
M~.  Our experiments also suggest  that  a  decrease in  M4~ sensitivity alone, without 
the loss of the strong T  cell-recognized antigen, influences the rate of tumor growth 
but  not  the  final  tumor  incidence.  However,  the  presence  of the  strong  T  cell- 
recognized antigen  may have overshadowed  the  possible contribution  of decreased 
M~-sensitivity  in  restraining  tumor  growth,  and  it  will  be  interesting  to  compare 
tumor variants derived  in  vitro that  have lost  the strong T  cell-recognized antigen 
and  either  have  lost  or  retained  sensitivity  to  M~.  We  consider  it  likely  that  the 
relative contribution of each of these cytolytic effector mechanisms will vary depend- 
ing on the phenotype of the tumor cells, and this is currently being analyzed using 
M~ and/or syngeneic cytolytic tumor-specific T  cell clones  (20)  as defined probes to 
reconstruct in a stepwise fashion in vitro the irnmunoselection for progressor variants 
that occurs in the intact host. 
Summary 
The ultraviolet radiation-induced fibrosarcoma 1591 is generally rejected by normal 
syngeneic mice, but occasionally the tumor succeeds in growing progressively. Analysis 
of these progressively growing tumors has regularly demonstrated the development of 
tumor variants that have acquired a heritable progressive growth potential. We have 
analyzed the phenotypic changes of these variants to determine which kind of  selection 
pressure had occurred during the evolution of the variants, thus  giving insight  into 
the relative importance and hierarchy of the different immune defense mechanisms 
that may be operating in normal individuals as a defense against neoplastic cells. We 
discovered that all of the host-selected progressor variants had lost not only a strong 
T  cell-recognized  and  tumor-specific  antigen,  but  also  their  high  sensitivity  to 
cytotoxic macrophages. No selection for macrophage-resistance or loss of the tumor 
antigen was observed in  1591 tumors reisolated from idiotypically-suppressed mice or 
from other  mice  lacking  tumor-specific T  cell  immunity.  Analysis  of other  tumor 
variants  selected  in  vitro  showed  that  1591 tumor cells  have the  potential  to  lose 
sensitivity to  tumoricidal  macrophages without  losing  the  T  cell-recognized  tumor 
antigen. Thus the data suggest that T  cells and macrophages act together to suppress 
the outgrowth of potentially malignant cells in vivo. JAMES  L.  URBAN AND  HANS  SCHREIBER  655 
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